News


29
OCT
2013

Leadscope® Announces New E. Coli Sal 102 A-T Mutation Statistical QSAR Model

New E. Coli model to be used in ICH M7 Guidance testing for Impurities by U.S. FDA

Columbus, Ohio - October 2013 - Leadscope® is pleased to announce the release of a new QSAR model E. Coli Sal 102 A-T Mutation (E. Coli) as part of the latest release of the Leadscope Model Applier Genetic Toxicity Statistical QSAR Suite. This model was developed under a Research Collaboration Agreement (RCA) between Leadscope and the U.S. Food ;amp Drug Administration (FDA).

This new E. Coli model along with the Leadscope Salmonella model will be used by the U. S. FDA in their testing under the ICH M7 Guidance for Impurities. The E. Coli model highlights alerting substructure and provides additional supportive evidence through the ability to perform analog searching of the Leadscope SAR Genetox Database.

Customers who license the Leadscope Model Applier - Genetic Toxicity Statistical QSAR Suite will receive the new E. Coli model at no additional cost.

Below is a summary of performance statistics for the E. Coli and Salmonella models:

The new version of the Model Applier provides a series of new reporting options that fully explain how the prediction was generated, including the REACH-compliant QPRF and QMRF report formats.

Leadscope will be exhibiting at the American College of Toxicology (ACT) Conference in San Antonio, Texas November 3-6, 2013. Please stop by our booth for a demonstration. If you are not attending the conference you may arrange for a demonstration of the new E. Coli or Salmonella models, by contacting Loftus Lucas at llucas@leadscope.com, Dr. Glenn Myatt at gmyatt@leadscope.com or Dr. Kevin Cross at kcross@leadscope.com. Or for further information, you may email Leadscope at info@leadscope.com.




26
OCT
2012

Version 2 of the Leadscope™ in vivo Rodent Carcinogenicity QSAR Model Suite is Now Available

Columbus, Ohio - October 2012 - Leadscope is pleased to announce the release of the updated in vivo Rodent Carcinogenicity QSAR Suite as part of the latest release of the Leadscope Model Applier. The models in this Suite were developed under a Research Collaboration Agreement with the U.S. Food and Drug Administration and have both improved accuracy and greater transparency.

Version 1 of the Rodent Carcinogenicity Suite included general scientific knowledge derived from proprietary compounds and data, so the chemical structures used to generate the prediction could not be inspected. In this update, all such data and chemical structures have either been declassified or removed. With this change, the product can fully explain the reasons behind any predictions, including highlighting any alerting or mitigating structural features as well as listing analogs from the training set.

The addition of new public compounds to the Model Suite brings the total compound count to 1,531 across the different model training sets. The models have improved sensitivity and were validated against a large external set of independent and non-overlapping carcinogenicity data. The Suite includes endpoint predictive models for the following in vivo rodent tests: rodent, mouse, rat, female mouse, male mouse, female rat, and male rat as well as the following in vitro tests: BALBc-3T3, C3H10T1-2, cell transformation, and SHE. Below is a summary of the predictive model metrics for the updated Rodent Carcinogenicity Suite in vivo models:

The improved version of the Leadscope Model Applier includes new reporting options that generate full prediction reports in bulk along with an option to produce REACH-compliant QPRF and QMRF reports.

Feel free to contact Glenn Myatt, Kevin Cross, or Leadscope if you are interested in the updated Rodent Carcinogenicity QSAR Model Suite.




5
OCT
2012

Statement on ACS v. Leadscope Settlement

Columbus, Ohio October 5, 2012: The American Chemical Society, Leadscope, Inc., and its three founders have reached a settlement of the litigation between them dating back to 2002. As a provision of the settlement, the parties have agreed that all right, title, interest and ownership in the Leadscope software and products that were the subject of the litigation belong exclusively to Leadscope. ACS will make a payment of $22,633,377.00 to settle and resolve all claims. Each party is pleased to put an end to this longstanding dispute.




3
APR
2009

Insilicofirst - New Collaboration in Toxicity Assessment

April 3, 2009 - Leadscope, Lhasa Limited, Multicase and Molecular Networks GmbH have launched a new collaboration providing toxicity assessment through a single common user interface. The new collaboration is Insilicofirst.

Insilicofirst brings together the world's leading organizations in toxicity prediction systems. This partnership combines highly regarded scientific knowledge with expertise in toxicity assessment through in silico predictive software development.

The initial phase of this collaboration, now available, is the development of a common user interface using the four founding partners' respective toxicity tools. Through insilicofirst.com scientists can obtain toxicity information, from all four partners, through a single query.

A query can be entered via a Mol/SD file, SMILES, Compound/Synonym Name or Registry Number. Data available includes model predictions, metabolism and reactivity) and published data. Users' initial search to see what data are available through Insilicofirst can be performed at no cost. The system completes a similarity search for analogs and also determines which models are appropriate for the query compound based on a domain of applicability analysis. Based on these analyses, the available products are shown along with their associated cost. Users can limit their search criteria by categories (i.e. carcinogenicity, genotoxicity, chronic, skin sensitization, etc), by product types (model predictions, metabolism and reactivity or published data) or by Vendors.

The Insilicofirst collaboration addresses the need to reduce the amount of time spent by scientists in referencing disparate sources of data to aid decision making related to toxicity assessment. Also, it will offer an efficient and cost-effective response to the EU REACH legislation and the desire to reduce animal testing.

To find out more about the Insilicofirst collaboration please visit insilicofirst.com.


Loftus Lucas CEO, Leadscope, Inc.

David Watson CEO, Lhasa Limited

Giles Klopman CEO, Multicase

Johann Gasteiger CEO, Molecular Networks, GmbH




25
MAR
2009

Leadscope to Collaborate with Prof. Klaus Kümmerer to provide Environmental Databases and Predictive Models

Columbus, Ohio March 25, 2009 - Leadscope is pleased to announce a collaboration with Prof. Klaus Kümmerer and his group at the University Medical Center Freiburg in Germany to develop high quality environmental databases and predictive models.

An initial series of high quality curated databases will be based on the OECD 301C test. Additional databases and models will become available in the coming months. These databases will be available through the Leadscope and the Insilicofirst web sites.

"We are pleased to be licensing the high quality environmental databases and predictive models from Prof. Klaus Kümmerer's group," explains Mr. Loftus Lucas, Leadscope's CEO. "These databases and models will immediately support product development needs and regulatory submission requirements".

Prof. Klaus Kümmerer explains, "The biodegradability databases and models to be made available will contain information curated from public sources and data generated in our laboratories".

About Leadscope, Inc.

Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.

About Prof. Klaus Kümmerer

Prof. Dr. Klaus Kümmerer, the founder of EDC, studied chemistry in Wurzburg and Tübingen and completed an additional training in ecology. He received his doctorate in 1990 from the Eberhard Karls University in Tübingen. Subsequently he became a manager in a private commercial research institution. He was awarded the title of professor in 1999 in the areas of environmental chemistry and environmental hygiene at the Albert Ludwig University in Freiburg. He has been a professor at the Department of Environmental Health Sciences at the University Medical Centre Freiburg since 2005. He is also the founder of EDC - Evaluation and Design of Chemicals.



13
MAR
2009

Insilico Software Specialists Launch a Pioneering Development in Toxicity Assessment at the 48th Annual SOT

(PRWEB) March 13, 2009 -- Lhasa Limited, together with partners Multicase, Leadscope and Molecular Networks GmbH, will unveil the Insilicofirst project at the 48th Annual Meeting of the Society of Toxicology. The Insilicofirst launch event will take place on Monday 16th March at 6pm at the Sheraton Inner Harbor. Invited delegates will be able to meet representatives from all four collaborating organisations, and find out more about the Insilicofirst system. There is no charge to participate in the session, nor is there a need to be registered for the SOT Annual Meeting.

The event will include a project overview and demonstration of the new Insilicofirst common user interface. In addition there will be an opportunity for networking, with refreshments provided.

There are only a limited number of places remaining, if you would like to be considered as a delegate, please email marketing@lhasalimited.org expressing why this project is of interest to you.

Insilicofirst brings together the world's leading organisations in toxicity prediction systems. This is a partnership combining highly regarded scientific knowledge with expertise in in silico predictive software development. This strategic alliance has a ground breaking plan to develop an integrated prediction system to support environmental toxicological assessment.

The four partners are currently completing the first step towards achieving their challenging objective, as development of a common user interface using their respective toxicity tools nears completion. The Insilicofirst alliance will soon begin work on an integrated prediction system to support environment toxicological assessment, an area not covered by their existing tools.

Via one simple interface the new environmental toxicity application will integrate tools commonly available for in silico prediction to provide data and predictions relating to the environmental impact of a chemical structure input by the user. Such a novel development has clear and appealing attraction to many players within the field of environmental toxicology.

The Insilicofirst collaboration will address the need to reduce the amount of time spent by scientists in referencing disparate sources of data to aid decision making related to environmental toxicity.

Also, it will offer an efficient and cost-effective response to the EU REACH legislation and the desire to reduce animal testing. Financial and time costs will be dramatically reduced through the provision of a predictive in silico device containing a high quality knowledge base built from diverse and reliable data sources.

At the 48th SOT meeting in March 2009, the Insilicofirst alliance will demonstrate for the first time the collaborative path they will pursue in creating the world's fastest and most user-friendly suite of tools to support the prediction of environmental toxicity.

If you would like to register your interest in this event please email marketing@lhasalimited.org. To find out more about the Insilicofirst project please visit www.Insilicofirst.com.



1
NOV
2008

Leadscope Announces the Appointment of Dr. Glenn Myatt as Chief Scientific Officer

Columbus, Ohio November 1, 2008 -- Leadscope announces the appointment of Dr. Glenn Myatt as Chief Scientific Officer. Dr. Myatt has held a number of scientific positions and was one of the founders of Leadscope in 1997.

"Dr. Myatt will be responsible for working with our customers and partners to ensure current and future products make a difference," says Loftus Lucas, CEO of Leadscope.

"With the recent completion of the FDA QSAR models, the FDA databases, the predictive data miner, and ToxML database builder, Leadscope is ideally position to provide a complete in silico discovery solution, " says Dr. Myatt. "I am excited to be taking on this new role".

About Leadscope, Inc.

Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.



17
AUG
2008

Leadscope Announces the Availability of the FDA QSAR Toxicity Models

Columbus, Ohio August 17, 2008 -- Leadscope announces the availability of the Leadscope FDA QSAR Toxicity Models.

Leadscope is making the FDA QSAR Toxicity Models available through a Cooperative Research & Development Agreement with the U.S. Food & Drug Administration (FDA). These models allow scientists to predict the potential toxicity and adverse human clinical effects of pharmaceuticals, cosmetics, food ingredients and other chemicals.

The Models are constructed by FDA scientists based on both proprietary and non-proprietary data. Leadscope technology allows delivery of models without disclosing any training sets.

The FDA QSAR Toxicity Models will be distributed via annual licenses in Suites containing multiple models relative to specific biological endpoints. The following Suites are now available:

Toxicity EndpointsHuman Clinical Endpoints
Rodent CarcinogenicityCardiological Adverse Effects
Genetic ToxicityHepatobiliary Adverse Effects
Reproductive ToxicityUrinary Tract Adverse Effects
Developmental Toxicity
Neurotoxicity
Misc. Toxicity Endpoints

A scientist may enter a single compound or a batch of compounds and receive predictions across multiple endpoints. The FDA QSAR Toxicity Models are a stand-alone product not requiring any other software or training.

Loftus Lucas, Leadscope's CEO, said, "The release of these FDA QSAR Toxicity Models culminates several years of work with the FDA to bring their toxicity data to scientists in an easy to use system. Scientists will get the same prediction from these Models as an FDA Regulator".

To view the FDA QSAR Model Suites visit Leadscope's website at www.leadscope.com/fda_qsar_models. For further information or to request on-line demonstration with a Leadscope scientist, contact us at info@leadscope.com.


1
AUG
2008

Leadscope Announces the Availability of the FDA SAR-Ready Carcinogenicity Database

Columbus, Ohio August 1, 2008 - Leadscope announces the availability of the FDA SAR-Ready Carcinogenicity Database.

The FDA SAR-Ready Carcinogenicity database has been constructed by Leadscope and the U.S. Food & Drug Administration (FDA) under their Cooperative Research & Development Agreement. This database contains 1,634 SAR structures with 9,557 test results, compiled from non-proprietary FDA records and other sources. Structures are provided in the SAR, neutral and tested forms.

All structures and test calls have been verified for accuracy while both structures and data have been balanced to facilitate model training set selection. Toxicity endpoints include Rat Male, Rat Female, Mouse Male and Mouse Female.

Loftus Lucas, Leadscope's CEO, said, "The combination of SAR-ready data and Leadscope's model building capability allows scientists to easily build and apply transparent carcinogenicity models".

To view a pre-recorded demonstration of the FDA SAR-Ready Carcinogenicity database, Click Here. For further information on this new database or to request on-line demonstration with a Leadscope scientist contact us at info@leadscope.com.

About Leadscope, Inc.

Leadscope's mission is to accelerate the drug discovery process by providing decision support based on regulatory and high quality data from research and development groups. The Company provides solutions which allow researchers to combine their own proprietary data with newly released U.S. FDA Toxicity Databases (based on the ToxML format).

The expertise of Leadscope includes an in-depth knowledge of advanced informatics and prediction technology along with the database services necessary to help organizations effectively analyze and visualize the valuable knowledge contained in research data.

Leadscope's customers include many pharmaceutical, chemical and consumer products companies, in addition to regulatory agencies in Europe, Japan, Canada and the United States.

Contact:
Loftus Lucas
CEO
Leadscope, Inc.
Phone: 614-340-1399
Email: info@leadscope.com

Shopping Cart
0 items